Remote Senior Oncology Account Manager — Drive Patient Access & Growth

Ladders; Omaha (NE); À distance; USD 150 000 - 230 000; Plein temps

Avantages offerts par ce poste

Cash compensation + equity

Health & wellness benefits

Learning & development

Patient-focused culture

Résumé du poste

Ladders is seeking a Senior Oncology Account Manager to lead the commercialization of an oncology portfolio across a remote US-based territory. This role emphasizes strong field execution, deep physician and patient access relationships, and flexible engagement strategies across virtual and in-person channels.

The ideal candidate brings extensive biopharma sales experience in oncology, a track record of launching oral oncolytics with companion diagnostics, and willingness to travel within the

Qualifications

• 12-15+ years of biopharma industry experience.
• 8-12+ years in oncology product sales with a proven track record.
• Experience launching oral oncolytics with companion diagnostics.
• Willingness to travel and reside in the territory.

Responsabilités

• Market the product portfolio in the designated territory.
• Exceed goals by positioning product benefits for patients.
• Coordinate with internal stakeholders for patient access.
• Adapt engagement strategies for virtual and in-person visits.
• Analyze market data to inform planning and optimize resources.
• Build deep customer relationships and offer innovative solutions.

Connaissances

12-15+ years biopharma experience

8-12+ years oncology sales

Oral oncolytics & companion DX exp

Willing to travel nationally

Formation

MA/MS/BA/BS degree

Description du poste

Ladders is seeking a Senior Oncology Account Manager to lead the commercialization of an oncology portfolio across a remote US-based territory. This role emphasizes strong field execution, deep physician and patient access relationships, and flexible engagement strategies across virtual and in-person channels.

The ideal candidate brings extensive biopharma sales experience in oncology, a track record of launching oral oncolytics with companion diagnostics, and willingness to travel within the